What are the recommended treatment options for anxiety in older adults, including non‑pharmacologic therapies and appropriate pharmacologic agents?

Anxiety Treatment for Older Adults

For older adults with anxiety, initiate an SSRI—specifically escitalopram or sertraline—as first-line pharmacotherapy, while simultaneously implementing non-pharmacologic interventions such as cognitive behavioral therapy (CBT) and avoiding benzodiazepines entirely due to their unacceptable risk profile in this population. 1, 2, 3

First-Line Pharmacologic Treatment

Preferred SSRIs

• Escitalopram and sertraline are the optimal initial choices because they demonstrate superior tolerability compared with other SSRIs while maintaining robust efficacy (NNT = 4.7) 1, 4
• Paroxetine may be considered when maximizing symptom reduction is the priority, though it carries slightly higher discontinuation rates due to side effects 1
• A 2025 meta-analysis of 2,336 older adults found antidepressants reduced anxiety symptoms with moderate certainty of evidence (SMD -1.19), with SSRIs showing greater efficacy (SMD -1.84) than SNRIs (SMD -0.46) 4

SNRI Alternative

• Venlafaxine extended-release is the recommended first-line alternative when SSRIs are contraindicated, not tolerated, or have failed after an adequate 9-12 week trial 1, 3
• Venlafaxine demonstrates comparable efficacy to SSRIs (NNT = 4.94) with similar dropout rates to placebo 1
• Monitor blood pressure and pulse regularly in patients receiving SNRIs, as sustained hypertension can occur 1

Dosing Strategy

• Start at low doses and titrate upward gradually to minimize treatment-emergent anxiety and gastrointestinal symptoms 1
• Once-daily dosing with extended-release formulations improves adherence 1

Critical Medications to Avoid

Benzodiazepines: Contraindicated

• Benzodiazepines should be avoided entirely in older adults due to dependence risk, lack of long-term efficacy data, and serious adverse events 1, 2, 3
• The American Geriatrics Society explicitly advises against benzodiazepine use in older adults 2
• A 2025 systematic review found evidence for benzodiazepine efficacy is "very uncertain with high risk of bias" 4
• Specific harms include: sedation, cognitive impairment, falls with injury, motor skill impairment, habituation, and withdrawal syndromes 5
• Midazolam poses particularly elevated risk of serious adverse events (16.8% rate) without any gains in clinical efficacy when used for agitation 6
• Lorazepam shows dose-dependent increases in adverse events 6

Other Agents to Avoid

• Hydroxyzine lacks guideline support as first-line treatment and is not included in contemporary treatment algorithms 1
• Antipsychotics carry an FDA black-box warning for increased mortality risk in elderly patients with dementia and should be avoided for anxiety management 5, 3

Non-Pharmacologic Interventions (Essential Component)

Cognitive Behavioral Therapy

• CBT specifically developed for anxiety disorders should be offered concurrently with pharmacotherapy 7, 8, 9
• Individual CBT sessions by a skilled therapist following structured protocols (Clark and Wells model or Heimberg model) are recommended 7
• If face-to-face CBT is not desired, self-help with support based on CBT principles is an acceptable alternative 7
• Brief CBT adapted for primary care shows large effect sizes (d = 1.06) and can be delivered in 6 sessions or fewer 8

Additional Non-Pharmacologic Options

• Music therapy compared with usual care shows significant benefit (SMD: -0.82) 10
• Massage therapy demonstrates substantial effects (SMD: -4.32) though with significant heterogeneity 10
• Sleep restriction-compression therapy for comorbid insomnia 2
• Person-centered communication and sensory therapy should always be attempted first in acute agitation 6

Safety Monitoring Requirements

For SSRIs and SNRIs

• Monitor for serotonin syndrome and neuroleptic malignant syndrome, the most serious adverse reactions 1
• Watch for common effects: somnolence, dizziness, nausea 1
• Screen for suicidal thoughts and behaviors, particularly in the first weeks of treatment 1
• Assess for behavioral activation, hypomania, and abnormal bleeding risk 1

For SNRIs Specifically

• Regular blood pressure and pulse monitoring to detect sustained hypertension 1

Treatment Duration and Maintenance

• Maintain successful pharmacologic treatment for 9-12 months after remission to minimize relapse risk 1
• If an initial SSRI fails after an adequate 9-12 week trial, switch to paroxetine for potentially greater symptom reduction 1
• Sustained reduction in depressive symptoms (which commonly co-occur with anxiety) is the primary mediator of long-term quality of life improvement 11

Common Pitfalls to Avoid

• Do not use benzodiazepines even for short-term "bridging" while waiting for antidepressant onset—the risks outweigh any theoretical benefit in older adults 2, 3
• Avoid intravenous or intramuscular administration of anxiolytics when oral routes are feasible, as parenteral routes increase adverse event risk 6
• Do not use escalating doses of anxiolytics; use the lowest effective dose 6
• Recognize that older adults may require longer time-to-response and lower doses compared with younger adults to reduce adverse events 6

Evidence Quality

The recommendations are grounded in 2023-2025 high-quality guidelines employing systematic GRADE methodology, including the Japanese Society of Neuropsychopharmacology guidelines (26 RCTs supporting SSRIs) and a 2025 Lancet Psychiatry meta-analysis of 19 studies involving 2,336 older adults 1, 4. The 2025 JAGS geriatric emergency department guidelines provide the most recent evidence on medication safety in older adults with agitation 6.